BR112016009214A8 - uso de um composto para preparação de um medicamento para o tratamento de distrofia muscular e composição farmacêutica - Google Patents

uso de um composto para preparação de um medicamento para o tratamento de distrofia muscular e composição farmacêutica Download PDF

Info

Publication number
BR112016009214A8
BR112016009214A8 BR112016009214A BR112016009214A BR112016009214A8 BR 112016009214 A8 BR112016009214 A8 BR 112016009214A8 BR 112016009214 A BR112016009214 A BR 112016009214A BR 112016009214 A BR112016009214 A BR 112016009214A BR 112016009214 A8 BR112016009214 A8 BR 112016009214A8
Authority
BR
Brazil
Prior art keywords
treatment
muscular dystrophy
compound
drug
preparation
Prior art date
Application number
BR112016009214A
Other languages
English (en)
Inventor
Jagerschmidt Catherine
Peixoto Christophe
D Bush Ernest
Sylvie Namour Florence
Nique Francois
Lefrancois Jean-Michael
Triballeau Nicolas
Deprez Pierre
Tom Burt Paul Wigerinck Piet
Blanque Roland
Original Assignee
Jagerschmidt Catherine
Peixoto Christophe
D Bush Ernest
Sylvie Namour Florence
Nique Francois
Jean Michael Lefrancois
Triballeau Nicolas
Deprez Pierre
Tom Burt Paul Wigerinck Piet
Blanque Roland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jagerschmidt Catherine, Peixoto Christophe, D Bush Ernest, Sylvie Namour Florence, Nique Francois, Jean Michael Lefrancois, Triballeau Nicolas, Deprez Pierre, Tom Burt Paul Wigerinck Piet, Blanque Roland filed Critical Jagerschmidt Catherine
Publication of BR112016009214A8 publication Critical patent/BR112016009214A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Nutrition Science (AREA)
  • Rheumatology (AREA)
  • Physiology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

resumo “métodos para tratamento de distrofias musculares” a presente invenção refere-se a, entre outras coisas, o tratamento de distrofia muscular (por exemplo, distrofia muscular de duchenne), por exemplo, utilizando uma composição, por exemplo, uma composição que compreende o composto (i), ou um seu sal farmaceuticamente aceitável, pró-fármaco e metabolito deste.
BR112016009214A 2013-10-25 2014-10-24 uso de um composto para preparação de um medicamento para o tratamento de distrofia muscular e composição farmacêutica BR112016009214A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361895832P 2013-10-25 2013-10-25
PCT/US2014/062178 WO2015061685A1 (en) 2013-10-25 2014-10-24 Methods for treatment of muscular dystrophies

Publications (1)

Publication Number Publication Date
BR112016009214A8 true BR112016009214A8 (pt) 2020-03-24

Family

ID=52993619

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016009214A BR112016009214A8 (pt) 2013-10-25 2014-10-24 uso de um composto para preparação de um medicamento para o tratamento de distrofia muscular e composição farmacêutica

Country Status (9)

Country Link
US (2) US20160250188A1 (pt)
EP (1) EP3060206A4 (pt)
JP (1) JP2016538269A (pt)
CN (1) CN105979943A (pt)
AU (1) AU2014339917A1 (pt)
BR (1) BR112016009214A8 (pt)
CA (1) CA2928235A1 (pt)
MX (1) MX2016005287A (pt)
WO (1) WO2015061685A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2643856B1 (es) 2016-05-24 2018-08-03 Universidad Del Pais Vasco / Euskal Herriko Unibertsitatea Triazoles para la regulación de la homeostasis de calcio intracelular
EP4066850A3 (en) * 2017-02-22 2022-11-23 Bioincept LLC Peptides and methods of treating dystrophy-related disorders using the same
EP3801510A4 (en) * 2018-06-05 2022-03-02 The Regents of the University of California METHODS OF TREATMENT OF MUSCULAR DYSTROPHIES
CN113924085A (zh) * 2019-04-12 2022-01-11 加利福尼亚大学董事会 用于增加肌肉量和氧化代谢的组合物和方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0715087D0 (en) * 2007-08-03 2007-09-12 Summit Corp Plc Drug combinations for the treatment of duchenne muscular dystrophy
GB2463514C (en) * 2008-09-11 2018-09-26 Galapagos Nv Imidazolidine compounds and uses therefor
ITBO20090078A1 (it) * 2009-02-13 2010-08-14 Consiglio Nazionale Ricerche Composti per il trattamento del tumore alla prostata e procedimenti per la loro sintesi

Also Published As

Publication number Publication date
WO2015061685A1 (en) 2015-04-30
EP3060206A4 (en) 2017-04-19
AU2014339917A1 (en) 2016-05-12
US20160250188A1 (en) 2016-09-01
US20190167640A1 (en) 2019-06-06
CN105979943A (zh) 2016-09-28
CA2928235A1 (en) 2015-04-30
JP2016538269A (ja) 2016-12-08
EP3060206A1 (en) 2016-08-31
MX2016005287A (es) 2017-02-22

Similar Documents

Publication Publication Date Title
CY1122786T1 (el) Δοσολογικα σχηματα για ενωσεις κατηγοριας εχινοκανδινης
BR112018008880A8 (pt) composto 7-(tiazol-5-il) pirrolopirimidina como agonista de tlr7
CL2018000318A1 (es) Compuestos derivados de piridinona, inhibidores de bromodominio; composición farmacéutica que los comprende; y su uso en el tratamiento de enfermedades del cáncer. (solicitud divisional 201600925)
CL2017000379A1 (es) Compuestos de pirrolopirimidina usados como agonistas del receptor de tipo toll. 7 (tlr7)
CO2018004857A2 (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer
GT201500053A (es) Composicion farmaceutica recubierta que contiene regorafenib
BR112015018738A8 (pt) compostos de tetra-hidropirrolotiazina, seus usos, e composição farmacêutica
BR112015029512A2 (pt) derivados de pirazolopirrolidina e seu uso no tratamento de doenças
BR112015021983A2 (pt) compostos heterocíclicos e usos dos mesmos
BR112015020302A2 (pt) derivado de pirazol
BR112014022214A2 (pt) fenólicos antibacterianos
BR112016011755A2 (pt) derivado de ureia ou sal farmacologicamente aceitável do mesmo
BR112015022972A2 (pt) composição farmacêutica de cloridrato de s-cetamina
CL2013002417A1 (es) Compuestos derivados de fluoropiridinona; composición farmacéutica que los comprende; y su uso en el tratamiento de infecciones bacterianas.
BR112013022495A2 (pt) formulação farmacêutica aquosa de tapentadol para administração oral
BR112015028212A2 (pt) derivado de fenol e método de preparação e utilização dos mesmos na medicina
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
BR112014018953A8 (pt) Derivados de lupano triterpenoide e uso farmacêutico dos mesmos
NI201500096A (es) Compuesto químicos
BR112016011170A8 (pt) derivados de heteroaril ácido butanoico, seus usos, combinação e composição farmacêutica
BR112015017251A2 (pt) composições farmacêuticas compreendendo doadores de nitroxil
BR112018001035A2 (pt) compostos de fenoxiacetamidas aneladas, sal farmaceuticamente aceitável, seu método de síntese, combinação de medicamento e uso dos mesmos
BR112018002115A2 (pt) benzamidas aneladas
BR112017012406A2 (pt) formulação com relação fixa de insulina glargina/lixisenatida
BR112022001568A2 (pt) Composto, método para preparação do composto, composição farmacêutica, e, uso do composto

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law
B07E Notice of approval relating to section 229 industrial property law

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: suspension of the patent application procedure
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements